{
    "info": {
        "nct_id": "NCT05949684",
        "official_title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The \"ELEMENT-MDS\" Trial",
        "inclusion_criteria": "Inclusion Criteria\n\n* Participant has documented diagnosis of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score) confirmed via bone marrow aspirate and:.\n\n  i) < 5% blasts in bone marrow and < 1% blasts in peripheral blood.\n* Participant is not transfusion dependent (NTD) based on IWG2018 criteria.\n* Participant is erythropoiesis-stimulating agent naive. Participants may be randomized at the investigator's discretion if the participant received no more than 2 prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa, with the last dose at least 8 weeks prior to randomization.\n* Participant has a baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L.\n* Participant has symptoms of anemia:.\n\n  i) Participant records a severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness performed during the screening period.\n* Participant has a baseline Hb concentration prior to randomization of ≤ 9.5 g/dL. The baseline Hb will be calculated using the mean of the two lowest available Hb measurements within 16 weeks prior to randomization and must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization). The two Hb measurements must have been performed at least seven days apart. Hb levels less than 21 days following RBC transfusion should not be used. Split samples for local assessments are not required.\n\nExclusion Criteria\n\n* Participant with secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).\n* Participant with known history of diagnosis of AML.\n* Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to randomization.\n* Participant with a history of pure red cell aplasia and/or antibody against erythropoietin.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Inclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Participant has symptoms of anemia:.",
                "criterions": [
                    {
                        "exact_snippets": "Participant has symptoms of anemia:",
                        "criterion": "anemia symptoms",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participant has symptoms of anemia:",
                        "criterion": "anemia symptoms",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "i) < 5% blasts in bone marrow and < 1% blasts in peripheral blood.",
                "criterions": [
                    {
                        "exact_snippets": "< 5% blasts in bone marrow",
                        "criterion": "blasts in bone marrow",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "< 1% blasts in peripheral blood",
                        "criterion": "blasts in peripheral blood",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "< 5% blasts in bone marrow",
                        "criterion": "blasts in bone marrow",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "< 1% blasts in peripheral blood",
                        "criterion": "blasts in peripheral blood",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant is not transfusion dependent (NTD) based on IWG2018 criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Participant is not transfusion dependent (NTD) based on IWG2018 criteria.",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Participant is not transfusion dependent (NTD) based on IWG2018 criteria.",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "definition standard",
                            "expected_value": "IWG2018 criteria"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participant is not transfusion dependent (NTD) based on IWG2018 criteria.",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Participant is not transfusion dependent (NTD) based on IWG2018 criteria.",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "definition standard",
                            "expected_value": "IWG2018 criteria"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant with known history of diagnosis of AML.",
                "criterions": [
                    {
                        "exact_snippets": "known history of diagnosis of AML",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known history of diagnosis of AML",
                        "criterion": "acute myeloid leukemia (AML) diagnosis",
                        "requirement": {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "i) Participant records a severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness performed during the screening period.",
                "criterions": [
                    {
                        "exact_snippets": "severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness",
                        "criterion": "PGI-S symptom severity (fatigue, weakness, shortness of breath, dizziness)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "PGI-S scale (moderate or greater)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness",
                        "criterion": "PGI-S symptom severity (fatigue, weakness, shortness of breath, dizziness)",
                        "requirement": {
                            "requirement_type": "number of symptoms meeting criterion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "symptom"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed during the screening period",
                        "criterion": "PGI-S assessment timing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during the screening period"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness",
                                "criterion": "PGI-S symptom severity (fatigue, weakness, shortness of breath, dizziness)",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "PGI-S scale (moderate or greater)"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "severity score of \"moderate\" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness",
                                "criterion": "PGI-S symptom severity (fatigue, weakness, shortness of breath, dizziness)",
                                "requirement": {
                                    "requirement_type": "number of symptoms meeting criterion",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "symptom"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "performed during the screening period",
                        "criterion": "PGI-S assessment timing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during the screening period"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to randomization.",
                "criterions": [
                    {
                        "exact_snippets": "history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident) ... within 6 months prior to randomization",
                        "criterion": "cerebrovascular accident",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of transient ischemic attack ... within 6 months prior to randomization",
                        "criterion": "transient ischemic attack",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of deep venous thrombosis (including proximal and distal) ... within 6 months prior to randomization",
                        "criterion": "deep venous thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of pulmonary or arterial embolism ... within 6 months prior to randomization",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of pulmonary or arterial embolism ... within 6 months prior to randomization",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of arterial thrombosis ... within 6 months prior to randomization",
                        "criterion": "arterial thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of other venous thrombosis within 6 months prior to randomization",
                        "criterion": "other venous thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident) ... within 6 months prior to randomization",
                        "criterion": "cerebrovascular accident",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of transient ischemic attack ... within 6 months prior to randomization",
                        "criterion": "transient ischemic attack",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of deep venous thrombosis (including proximal and distal) ... within 6 months prior to randomization",
                        "criterion": "deep venous thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of pulmonary or arterial embolism ... within 6 months prior to randomization",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of pulmonary or arterial embolism ... within 6 months prior to randomization",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of arterial thrombosis ... within 6 months prior to randomization",
                        "criterion": "arterial thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of other venous thrombosis within 6 months prior to randomization",
                        "criterion": "other venous thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Participant has a baseline Hb concentration prior to randomization of ≤ 9.5 g/dL. The baseline Hb will be calculated using the mean of the two lowest available Hb measurements within 16 weeks prior to randomization and must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization). The two Hb measurements must have been performed at least seven days apart. Hb levels less than 21 days following RBC transfusion should not be used. Split samples for local assessments are not required.",
                "criterions": [
                    {
                        "exact_snippets": "Participant has a baseline Hb concentration prior to randomization of ≤ 9.5 g/dL.",
                        "criterion": "baseline hemoglobin (Hb) concentration",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9.5,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "The baseline Hb will be calculated using the mean of the two lowest available Hb measurements within 16 weeks prior to randomization",
                        "criterion": "hemoglobin (Hb) measurements timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 16 weeks prior to randomization"
                        }
                    },
                    {
                        "exact_snippets": "must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization)",
                        "criterion": "central lab hemoglobin (Hb) reading",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization)",
                        "criterion": "central lab hemoglobin (Hb) reading",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within the screening period (no more than 35 days before randomization)"
                        }
                    },
                    {
                        "exact_snippets": "The two Hb measurements must have been performed at least seven days apart.",
                        "criterion": "hemoglobin (Hb) measurements interval",
                        "requirement": {
                            "requirement_type": "interval between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hb levels less than 21 days following RBC transfusion should not be used.",
                        "criterion": "hemoglobin (Hb) measurement post-RBC transfusion",
                        "requirement": {
                            "requirement_type": "exclusion period after RBC transfusion",
                            "expected_value": {
                                "operator": "<",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participant has a baseline Hb concentration prior to randomization of ≤ 9.5 g/dL.",
                        "criterion": "baseline hemoglobin (Hb) concentration",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 9.5,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "The baseline Hb will be calculated using the mean of the two lowest available Hb measurements within 16 weeks prior to randomization",
                        "criterion": "hemoglobin (Hb) measurements timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 16 weeks prior to randomization"
                        }
                    },
                    {
                        "exact_snippets": "must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization)",
                        "criterion": "central lab hemoglobin (Hb) reading",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must include at least one central lab Hb reading done within the screening period (no more than 35 days before randomization)",
                        "criterion": "central lab hemoglobin (Hb) reading",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within the screening period (no more than 35 days before randomization)"
                        }
                    },
                    {
                        "exact_snippets": "The two Hb measurements must have been performed at least seven days apart.",
                        "criterion": "hemoglobin (Hb) measurements interval",
                        "requirement": {
                            "requirement_type": "interval between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hb levels less than 21 days following RBC transfusion should not be used.",
                        "criterion": "hemoglobin (Hb) measurement post-RBC transfusion",
                        "requirement": {
                            "requirement_type": "exclusion period after RBC transfusion",
                            "expected_value": {
                                "operator": "<",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant has a baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L.",
                "criterions": [
                    {
                        "exact_snippets": "baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L",
                        "criterion": "serum erythropoietin (sEPO) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "U/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L",
                        "criterion": "serum erythropoietin (sEPO) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "U/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant is erythropoiesis-stimulating agent naive. Participants may be randomized at the investigator's discretion if the participant received no more than 2 prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa, with the last dose at least 8 weeks prior to randomization.",
                "criterions": [
                    {
                        "exact_snippets": "Participant is erythropoiesis-stimulating agent naive.",
                        "criterion": "prior erythropoiesis-stimulating agent use",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Participants may be randomized at the investigator's discretion if the participant received no more than 2 prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                        "criterion": "prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                        "requirement": {
                            "requirement_type": "number of prior doses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the last dose at least 8 weeks prior to randomization",
                        "criterion": "time since last dose of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                        "requirement": {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participant is erythropoiesis-stimulating agent naive.",
                        "criterion": "prior erythropoiesis-stimulating agent use",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants may be randomized at the investigator's discretion if the participant received no more than 2 prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                                "criterion": "prior doses of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                                "requirement": {
                                    "requirement_type": "number of prior doses",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "doses"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "with the last dose at least 8 weeks prior to randomization",
                                "criterion": "time since last dose of epoetin alfa, epoetin alfa biosimilar, or darbepoetin alfa",
                                "requirement": {
                                    "requirement_type": "time since last dose",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Other protocol-defined Inclusion/Exclusion criteria apply.",
                "criterions": [
                    {
                        "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                        "criterion": "other protocol-defined inclusion/exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                        "criterion": "other protocol-defined inclusion/exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participant with a history of pure red cell aplasia and/or antibody against erythropoietin.",
                "criterions": [
                    {
                        "exact_snippets": "history of pure red cell aplasia",
                        "criterion": "pure red cell aplasia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "antibody against erythropoietin",
                        "criterion": "antibody against erythropoietin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of pure red cell aplasia",
                        "criterion": "pure red cell aplasia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "antibody against erythropoietin",
                        "criterion": "antibody against erythropoietin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Participant with secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).",
                "criterions": [
                    {
                        "exact_snippets": "secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases)",
                        "criterion": "secondary myelodysplastic syndrome (MDS)",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "chemical injury",
                                "treatment with chemotherapy",
                                "treatment with radiation for other diseases"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participant has documented diagnosis of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score) confirmed via bone marrow aspirate and:.",
                "criterions": [
                    {
                        "exact_snippets": "documented diagnosis of MDS according to World Health Organization (WHO) 2016",
                        "criterion": "myelodysplastic syndrome (MDS) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "documented diagnosis of MDS according to World Health Organization (WHO) 2016",
                        "criterion": "myelodysplastic syndrome (MDS) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "World Health Organization (WHO) 2016"
                        }
                    },
                    {
                        "exact_snippets": "meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score)",
                        "criterion": "IPSS-R risk classification",
                        "requirement": {
                            "requirement_type": "risk_category",
                            "expected_value": [
                                "very low",
                                "low",
                                "intermediate"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score)",
                        "criterion": "IPSS-R risk classification",
                        "requirement": {
                            "requirement_type": "intermediate-risk score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.5,
                                "unit": "IPSS-R score"
                            }
                        }
                    },
                    {
                        "exact_snippets": "confirmed via bone marrow aspirate",
                        "criterion": "bone marrow aspirate confirmation",
                        "requirement": {
                            "requirement_type": "confirmation_method",
                            "expected_value": "bone marrow aspirate"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}